Drug Repurposing: Why the Pharmaceutical Industry's Best New Drugs May Already Exist

 The conventional narrative of drug discovery runs in one direction: a novel compound is identified, optimized, tested, and — if everything goes well — approved. The molecule is new. The target is new. The therapeutic indication is new. The development timeline is long, the attrition is high, and the cost is enormous.

Drug repurposing runs the same process in reverse. The molecule already exists. Its safety profile in humans is already known. Its manufacturing process is established. The question is not whether it is safe to give to people — that has been answered — but whether it does something useful in a disease for which it was not originally developed.

This is not a niche strategy. Historical examples include sildenafil citrate transitioning from a cardiovascular compound to an erectile dysfunction treatment, and thalidomide shifting from a sedative to a foundational immunomodulatory agent in multiple myeloma — drugs that found their most important clinical applications not in the indications for which they were designed, but in diseases discovered through observation, serendipity, and scientific curiosity. These are not outliers. They are the clearest illustrations of a principle that the pharmaceutical industry is now pursuing systematically: the biology of existing drugs is richer than their approved labels suggest.

Why Drug Repurposing Has Accelerated

Several converging forces have made drug repurposing more scientifically tractable and more commercially attractive than at any previous point in the industry's history.

The explosion of biological and clinical data available for analysis has transformed what is possible. By leveraging the established safety and efficacy profiles of existing drugs, repurposing can significantly reduce the time, cost, and risk associated with traditional drug development, while providing a valuable pathway for addressing unmet medical needs. But the practical ability to identify repurposing opportunities at scale has historically been limited by the difficulty of systematically mining the relevant data — preclinical pharmacology, clinical adverse event patterns, transcriptomic signatures, network pharmacology relationships — across thousands of approved compounds simultaneously.

Artificial intelligence has changed that. AI-based platforms can analyze gene expression data, protein interaction networks, electronic health records, adverse event databases, and published literature at a scale and speed that no human team can match — identifying pharmacological relationships between approved drugs and disease pathways that would be invisible to conventional analysis. The same generative AI capabilities driving the discovery of new compounds like Rentosertib are increasingly being applied to the repurposing of existing ones.

The COVID-19 pandemic provided the most dramatic demonstration of drug repurposing at accelerated scale. The urgent search for COVID-19 treatments generated an extraordinary volume of repurposing clinical trials — with more than 4,952 clinical trials registered on ClinicalTrials.gov by March 2021, evaluating existing drugs including remdesivir, dexamethasone, baricitinib, and tocilizumab. The outcomes were mixed, but the exercise validated the clinical research infrastructure for rapid repurposing evaluation and produced genuine therapeutic discoveries — dexamethasone's role in reducing COVID-19 mortality being the most consequential.

Most recently, nitisinone — a compound originally developed as a herbicide and later approved for hereditary tyrosinemia type 1 — received FDA approval in 2025 for alkaptonuria, becoming the first targeted therapy for this ultra-rare metabolic disease after 25 years of research. The molecule was not new. The clinical need it addressed was profound and previously unmet.

The Clinical Development Advantage — and Its Limits

The most compelling aspect of drug repurposing from a development perspective is what does not need to be done. Toxicology studies across multiple species. Safety pharmacology assessments. Manufacturing process development. First-in-human dose escalation studies to establish maximum tolerated dose and pharmacokinetic profile.

For an approved drug being evaluated in a new indication, much of this pre-clinical and Phase I work is already complete. The known safety profile means that Phase II proof-of-concept studies can sometimes begin with a level of confidence in the compound's tolerability that a novel molecule cannot offer. The known pharmacokinetics mean that dose selection for the new indication can build on an established human data foundation rather than extrapolating from animal models.

Access to drugs already approved enables off-label clinical studies without the need for new GMP production, lowering trial barriers. The manufacturing supply chain is established. Regulatory submissions can reference the existing safety dossier rather than building a new one from scratch.

These advantages are real and significant. But they come with constraints that define what repurposing clinical programs need to do differently from conventional new drug development.

The indication specificity challenge. An approved drug's safety profile was characterized in a specific patient population, at a specific dose, for a specific duration of use. The new indication may involve a different patient population with different comorbidities, different concomitant medications, and different baseline organ function. The safety data from the original indication cannot be assumed to fully characterize the risk in the new indication. Phase II and III programs for repurposed drugs must include safety evaluation appropriate to the new patient population — not simply reference the existing label.

The dose may be different. The dose that was optimal for the original indication may not be optimal — or even appropriate — for the new one. Sildenafil for pulmonary arterial hypertension is dosed very differently from sildenafil for erectile dysfunction. Thalidomide's immunomodulatory applications require dose regimens that would not have been derived from its original sedative use. The clinical program for a repurposed drug must establish the appropriate dose for the new indication — which may require dose-finding studies that parallel the Phase I/II work done for the original compound.

The mechanism may be different. One of the most scientifically interesting aspects of drug repurposing is that the mechanism of action in the new indication may not be the same as in the original one. Repurposed drugs such as metformin and minoxidil demonstrate the clinical potential of repositioning strategies guided by mechanistic insight, phenotypic screening, and real-world observations — where the observed clinical effect in a new context reveals biology that was not the original pharmacological target. Understanding the mechanism of action in the new indication is important both for clinical development strategy and for regulatory submission — regulators will want to understand why the drug works in the new context, not just whether it does.

---

Regulatory Pathways for Repurposed Drugs

The regulatory landscape for drug repurposing is more nuanced than the simplified narrative of "already approved, therefore easier to develop" suggests.

In the United States, a repurposed drug seeking a new indication requires a supplemental NDA if the original sponsor is pursuing the new indication, or a full NDA or 505(b)(2) application if a different company is developing the new indication. The 505(b)(2) pathway — which allows reliance on the FDA's existing findings of safety and effectiveness for a previously approved drug — is the most commonly used regulatory mechanism for repurposing by non-originators. It requires the sponsor to demonstrate that the referenced data is scientifically appropriate for the new application and to address any differences in population, dose, route, or formulation.

The FDA's stance on real-world evidence for repurposing has shifted dramatically in recent years. In December 2025, FDA eliminated a major barrier by stating that submissions need not include individual-level patient data from real-world data sources — and a May 2026 initiative opened stakeholder input on using case reports, observational studies, and registry data as components of the repurposing evidence package. This evolution makes the regulatory pathway for repurposing, particularly in rare diseases and underserved indications, meaningfully more accessible than it was even five years ago.

In India, CDSCO's framework for repurposing is evolving. For drugs already approved in India being evaluated for new indications, the regulatory pathway builds on the existing drug master file, with the clinical trial application for the new indication evaluated in the context of the established safety dossier. The January 2026 NDCT amendments, which streamlined several regulatory processes, are beneficial for repurposing programs that involve BA/BE studies or non-clinical testing — reducing the administrative overhead at the early development stages.

---

India as a Location for Drug Repurposing Clinical Programs

India's clinical research infrastructure offers several specific advantages for drug repurposing programs that are worth understanding explicitly.

Disease prevalence and population diversity. Many of the most interesting repurposing opportunities — metabolic disease, fibrotic conditions, inflammatory disorders, rare genetic diseases, infectious disease — are prevalent in India at high rates, providing the patient access needed for efficient clinical proof-of-concept evaluation. Drug repurposing successes in rare diseases, including nitisinone for alkaptonuria and sirolimus for rare vascular anomalies, illustrate the value of patient populations that are rare globally but may be more accessible in India's large and diverse population.

Cost and speed for proof-of-concept. The Phase II proof-of-concept study is often the most critical and most cost-sensitive stage of a repurposing program — the study that determines whether the investment in a full Phase III program is justified. Conducting these studies in India at 40 to 60 percent of Western costs, with faster site activation and recruitment timelines, substantially improves the economics of repurposing programs that may be pursued by academic groups, patient advocacy organizations, or small biotech companies rather than large pharmaceutical sponsors.

AI-supported target identification. AI algorithms are transforming drug repurposing by revealing new therapeutic targets and mechanisms — and the integration of omics data with computational modeling enhances target identification and validation in repurposing studies. Indian research institutions and bioinformatics groups are increasingly active in this space, creating opportunities for academic-industry collaborations that identify repurposing candidates and partner with CROs to translate them into clinical programs.

---

What Drug Repurposing Programs Need From a Clinical Research Partner

A CRO supporting a drug repurposing clinical program needs to bring a specific combination of capabilities that differs from conventional new drug development support.

Regulatory strategy for the new indication, building on but not simply referencing the existing approval, requires regulatory expertise in the repurposing pathway — 505(b)(2) in the US, the analogous mechanisms in the EU and India — and the scientific judgment to identify what the new clinical program must demonstrate and what it can appropriately reference from the existing dossier.

Clinical study design for proof-of-concept in the new indication requires understanding of the disease biology, the appropriate patient population, and the endpoints that are validated in the new therapeutic context — which may be quite different from the endpoints used in the original indication's development program.

Safety monitoring designed for the new population — not simply referenced from the existing label — requires pharmacovigilance expertise and the clinical judgment to identify where the safety assumptions from the original indication may not fully apply.

And the biomarker strategy — confirming that the repurposed drug is engaging its target in the new indication and producing the expected pharmacodynamic effect — is often more important in repurposing programs than in conventional development, because the mechanism of action in the new context may not be as well established as in the original indication.

Conclusion

Drug repurposing is not a shortcut. It is a scientifically rigorous and commercially intelligent strategy for accelerating the delivery of medicines to patients who need them — by building on the biological knowledge embedded in existing drugs rather than starting from zero. The savings in time, cost, and pre-clinical work are real. The clinical development work that remains — proving efficacy in the new indication, establishing the appropriate dose, characterizing safety in the new patient population, and navigating the regulatory pathway — is substantial and requires exactly the same scientific and operational rigor as conventional drug development.

The difference is that repurposing programs start from a place of greater biological knowledge. Used well, that head start can transform the economics and the timeline of clinical development in ways that benefit not just sponsors and developers, but the patients waiting for the therapies they need.

At Genelife Clinical Research, we support Phase II and III clinical programs for repurposed small molecules — from regulatory strategy and proof-of-concept study design through clinical execution, statistical analysis, and regulatory submission support — in India and for international markets.

Bioavailability and Bioequivalence Studies: The Science, the Strategy, and What Makes Them Work

Bioavailability and bioequivalence studies sit at a critical junction in pharmaceutical development. For generic drug manufacturers, a successful BE study is the gateway to market — the regulatory demonstration that their product delivers the same therapeutic effect as the reference listed drug. For innovator companies, BA studies are the scientific foundation for formulation decisions, dose selection, and the clinical development strategy that follows. In both cases, the quality of the study determines not just whether a regulatory submission is accepted, but how quickly, how cleanly, and at what cost.

Yet BA/BE studies are frequently approached as though they are straightforward, low-risk exercises — simpler than Phase III trials, less demanding than NDA-level submissions. This is a costly misunderstanding. BA/BE studies are scientifically precise, operationally demanding, and highly sensitive to design and execution errors. A study that is well-designed but poorly executed, or well-executed but poorly designed, produces data that regulators reject — and the cost of a repeat study, compounded by the delay to market, dwarfs the cost of getting it right the first time.

This article breaks down what BA/BE studies actually involve, where the complexity lies, and what it takes to execute them in a way that generates data that stands up to regulatory scrutiny — whether that scrutiny comes from the DCGI, the US FDA, or the EMA.

Understanding the Difference: Bioavailability vs. Bioequivalence

The terms are often used interchangeably, but they measure different things and serve different purposes.

Bioavailability is a measure of the rate and extent to which an active pharmaceutical ingredient is absorbed from a formulation and becomes available at the site of action. For oral drug products, bioavailability is typically characterized by the plasma concentration-time profile of the drug following administration — specifically the area under the curve (AUC), the maximum plasma concentration (Cmax), and the time to reach maximum concentration (Tmax). Absolute bioavailability compares the systemic exposure from a non-intravenous formulation against intravenous administration; relative bioavailability compares two non-intravenous formulations against each other.

BA studies are used throughout drug development — to characterize new chemical entities, to compare formulations at different stages of development, to understand the impact of food on absorption, to assess drug-drug interactions at the absorption level, and to support bridging between formulations used in clinical trials and the final commercial product.

Bioequivalence is a regulatory concept rather than a purely pharmacokinetic one. Two products are bioequivalent if their rate and extent of absorption are sufficiently similar that they can be expected to produce the same therapeutic effect. Regulatory agencies have defined "sufficiently similar" in precise statistical terms: the 90% confidence intervals for the ratio of the test to reference AUC and Cmax must fall within the 80–125% acceptance limits — a criterion that seems simple but carries significant implications for study design and execution.

BE studies are the cornerstone of the generic drug approval pathway. They allow a generic manufacturer to demonstrate, without repeating the full clinical trial program, that their product is therapeutically equivalent to the reference listed drug. They are also used by innovator companies when making post-approval manufacturing changes, formulation modifications, or scale-up variations that require demonstration of continued bioequivalence with the approved product.

The Regulatory Landscape: India, US FDA, and EMA

BA/BE requirements are broadly similar across major regulatory jurisdictions, but the specifics differ in ways that matter significantly for study design — particularly for companies seeking approvals in multiple markets simultaneously.

In India, BA/BE studies are conducted under the New Drugs and Clinical Trials Rules, 2019, with CDSCO and DCGI oversight. The regulatory requirements align broadly with WHO guidelines, and the 80–125% acceptance criterion applies for most products. India has a well-established infrastructure for BA/BE study conduct, with several DCGI-approved facilities capable of conducting studies to the required standards. For generic drug approvals in India, BE studies conducted at approved Indian sites are acceptable. For products seeking ANDA approval in the US or generic approval in the EU, the study must meet the additional requirements of those jurisdictions — including potentially more stringent site qualification standards.

The US FDA's requirements for BE studies, articulated in its guidance documents for specific drug products and its general guidance on bioequivalence, are the most comprehensively documented and the most frequently cited globally. Product-specific guidance documents — which the FDA issues for individual reference listed drugs — specify the recommended study design, the recommended reference product, the recommended PK metrics, and any product-specific acceptance criteria that deviate from the standard 80–125% window. For highly variable drugs, narrow therapeutic index drugs, and locally acting products, the FDA has specific guidance that significantly affects study design requirements.

The EMA's framework, articulated in its guideline on the investigation of bioequivalence, is broadly aligned with the FDA's approach but has its own specific requirements around reference product selection, the treatment of highly variable drugs, and the statistical methodology for equivalence testing. For companies targeting both US and EU markets, designing a study that satisfies both sets of requirements simultaneously — rather than conducting separate studies for each market — requires careful upfront planning and is one of the more strategically valuable things an experienced CRO partner can contribute.

Study Design: Where Success or Failure Is Determined

The design of a BA/BE study is where the majority of regulatory submissions either gain or lose ground. The most common design for oral drug products is a two-period, two-sequence crossover study — each participant receives both the test and reference products in randomized sequence, separated by a washout period sufficient to eliminate carry-over effects. This design is efficient because each participant serves as their own control, substantially reducing the variability that must be accounted for in the sample size calculation.

But the crossover design is not universal. For drugs with very long half-lives, for which an adequate washout period would make the study impractically long, a parallel group design may be more appropriate. For highly variable drugs — where intra-subject variability in PK parameters exceeds 30% — reference-scaled average bioequivalence or replicate crossover designs may be required or recommended. For drugs with non-linear pharmacokinetics, single-dose studies may underestimate the differences that emerge at steady state, requiring additional multiple-dose assessment.

Getting the design right requires a thorough understanding of the pharmacokinetics of the reference product — its half-life, its variability, its absorption characteristics, any known food effects, and any known drug-drug interactions that must be managed in the study population. It requires a clear understanding of the regulatory expectations for the specific product being studied — which may differ from the general framework if product-specific guidance exists. And it requires prospective consideration of the statistical analysis plan — because the design and the analysis are inseparable, and a design that does not support the required statistical inference is not recoverable after the data is collected.

Sample Size and Power: The Hidden Risk

The sample size of a BA/BE study is calculated to provide adequate statistical power to conclude bioequivalence — assuming the test and reference products are truly bioequivalent. The calculation depends on three inputs: the expected ratio of test to reference for the primary PK metrics, the intra-subject variability of those metrics, and the acceptance criterion.

The most common error in BA/BE sample size calculation is underestimating variability. Variability estimates taken from the literature or from small pilot studies are frequently optimistic — because published studies have selection bias toward positive results, and small pilot studies have high uncertainty in their variability estimates. A study powered on an optimistic variability assumption will fail to achieve the required confidence interval width if the actual variability is higher — and the study will need to be repeated.

For highly variable drugs, this risk is particularly acute. When intra-subject variability for Cmax or AUC exceeds 30%, the sample sizes required to achieve the standard 80–125% confidence interval with adequate power become very large — sometimes 60 to 100 subjects or more. Reference-scaled average bioequivalence approaches, which adjust the acceptance criterion based on the observed variability of the reference product, can substantially reduce the sample size required — but require a replicate study design and specific statistical methodology that must be pre-specified in the protocol.

The investment in a robust, conservative sample size calculation — and in a pilot PK study to anchor the variability assumptions before the pivotal study is designed — is one of the highest-return investments a sponsor can make. A failed pivotal study costs more in time and money than any number of well-designed pilot studies.

Site Selection: A Strategic, Not Administrative Decision

The selection of the clinical site for a BA/BE study is a decision that deserves more strategic attention than it typically receives. In India, BA/BE studies must be conducted at sites that are approved by the DCGI and equipped with the analytical, clinical, and data management infrastructure required to conduct the study to GCP and regulatory standards.

The clinical component of a BA/BE study requires careful management of standardized conditions — fasting or fed state as per the protocol, standardized meals of defined composition, controlled water intake, precise sample collection timing, and rigorous participant management to prevent protocol deviations that would compromise the pharmacokinetic data. Sites with experienced clinical staff, well-defined SOPs for study conduct, and a strong track record in BA/BE study execution are substantially less likely to generate data that requires query, explanation, or rejection.

The bioanalytical component is equally critical. The assay used to measure drug concentrations in plasma or other biological matrices must be validated to meet regulatory requirements — including demonstration of selectivity, sensitivity, linearity, accuracy, precision, recovery, and stability under the conditions used in the study. Bioanalytical method validation is a detailed and exacting process, and the quality of the validation data directly determines the credibility of the pharmacokinetic results derived from it.

For studies intended to support submissions to multiple regulatory authorities, site qualification must account for the requirements of each target jurisdiction. A site that is DCGI-approved may or may not have the additional documentation, quality systems, and inspection history required to support an FDA ANDA submission. Understanding these requirements before site selection — rather than discovering gaps during the regulatory review — is a function of experience and advance planning.

Project Management: The Operational Architecture of a Successful Study

BA/BE studies have a compressed operational timeline relative to clinical trials — but they are not operationally simple. The coordination required between the clinical site, the bioanalytical laboratory, the data management team, the regulatory affairs function, and the sponsor is substantial, and the consequences of coordination failures — delayed sample analysis, protocol deviations, data integrity questions — are direct and immediate.

Effective project management for a BA/BE study begins with a detailed project plan that maps every activity from protocol finalization through regulatory submission, assigns responsibility, establishes timelines and dependencies, and identifies the critical path. Study startup activities — protocol approval, ethics committee submission and approval, site initiation, participant recruitment and screening, investigational product procurement — must be managed in parallel wherever possible, because delays at any point extend the overall timeline.

Participant recruitment deserves particular attention. BA/BE studies typically enroll healthy volunteers — a population that is generally easier to recruit than patient populations for therapeutic trials, but that still requires careful screening against protocol eligibility criteria. Participants with relevant comorbidities, concurrent medications, or genetic polymorphisms affecting drug metabolism may need to be excluded. Adequate recruitment timelines and screening-to-enrolment ratios must be built into the project plan.

During study execution, real-time oversight of protocol compliance — sampling times, meal standardization, confinement procedures, adverse event monitoring — is essential. Deviations from the protocol that affect the pharmacokinetic data are the most common cause of regulatory questions, and preventing them through rigorous site oversight is far more effective than addressing them in the clinical study report.

The Clinical Study Report: Where the Data Becomes the Submission

The clinical study report for a BA/BE study is the primary document that regulators review when evaluating a bioequivalence submission. It must present the pharmacokinetic data completely and transparently, describe the statistical analysis in detail, and provide a clear narrative that allows the reviewer to assess the validity of the study design, the integrity of the data, and the robustness of the bioequivalence conclusion.

Common deficiencies in BE clinical study reports — missing or inadequate bioanalytical validation data, insufficient description of protocol deviations and their impact, inadequate justification of the statistical model, or incomplete presentation of individual subject data — are among the most frequent causes of regulatory queries and complete response letters. A well-written, complete, and internally consistent clinical study report that anticipates regulatory questions and addresses them proactively is a substantially better regulatory asset than one that is technically accurate but incomplete or poorly organized.

Conclusion: BA/BE Studies Done Right

Bioavailability and bioequivalence studies are among the most scientifically precise and operationally demanding activities in pharmaceutical development. They are also, when conducted well, one of the most efficient mechanisms for generating the regulatory evidence needed to bring a drug product to market — whether that product is a generic seeking its first approval, a new formulation of an established drug, or an innovator product navigating post-approval change management.

The investment in getting BA/BE studies right — in study design, in site selection, in bioanalytical validation, in project management, and in clinical study report preparation — is an investment in the speed, the completeness, and the credibility of the regulatory submission that follows. In a competitive generics market where first-to-file and first-to-market advantages are measured in months, that investment pays back many times over.

At Genelife Clinical Research, our BA/BE capabilities span the full study lifecycle — from regulatory strategy and protocol design through site selection and management, clinical execution, bioanalytical coordination, data management, and clinical study report preparation. We work with both generic manufacturers and innovator companies across DCGI, US FDA, and EMA submission requirements, bringing the scientific rigor and operational discipline that BA/BE studies demand.

---

To learn more about Genelife's BA/BE and non-clinical study services, visit genelifecr.com.

Related Insights

Clinical Trial Process in India: Step-by-Step Guide

Genelife Perspective of Best Practices in Study Management

What is a CRO? Role of Clinical Research Organizations in India

Learn more about our clinical research services for end-to-end clinical trial support

The Constraints in Medical Device Clinical Trials: Why Device Research Is Harder Than It Looks

 Medical device clinical trials occupy a peculiar position in the clinical research landscape. They are, in many respects, held to the same evidentiary standards as pharmaceutical trials — demonstrating safety and efficacy before market approval, generating data that will withstand regulatory scrutiny, and producing evidence rigorous enough to change clinical practice. But the scientific and operational conditions under which they must do this are fundamentally more demanding than most drug trials — and the constraints that shape them are more varied, more persistent, and in some cases more intractable.

Understanding these constraints is not merely an academic exercise. For device companies planning clinical programs, for sponsors designing studies, and for CROs executing them, the constraints of medical device clinical research are the terrain that must be navigated — and navigating them well is the difference between a clinical program that delivers regulatory success and market credibility, and one that generates inconclusive data at substantial cost.

This article examines the seven most consequential constraints in medical device clinical research today — and what the current state of science, regulation, and methodology offers as a response to each.

1. The Absent Control: The Problem That Defines Medical Device Research

In pharmaceutical clinical research, the randomized placebo-controlled trial is the methodological gold standard. A patient receives either the investigational drug or an identical-appearing placebo. Neither patient nor investigator knows which. Outcomes are measured. The treatment effect is isolated with statistical precision.

This model does not exist in medical device research — and understanding why is the starting point for understanding everything else that makes device trials distinctive.

A patient cannot receive a placebo cardiac stent. A surgeon cannot be blinded to whether they are performing a real or sham hip replacement. A patient who has received a cochlear implant knows they have received it. The very nature of medical devices — physical objects that interact mechanically, electrically, or biologically with the body — makes the placebo-controlled design either practically impossible or ethically unacceptable in most device categories.

The result is a landscape of imperfect controls, each carrying its own methodological limitations. Surgical comparators are themselves operator-dependent and procedurally variable. Pharmacological comparators treat a different dimension of the same condition. Earlier device generations embody a different technological state than the device under investigation. And no-treatment comparators are often ethically unjustifiable for conditions where standard of care exists.

The consequence — inconclusive comparative effectiveness data, ambiguous results, prolonged clinical debates — is visible across the history of device research. The stent-versus-bypass-surgery debate, which has generated decades of landmark trials including SYNTAX, FREEDOM, and EXCEL, illustrates the problem clearly: even with exceptional trial design and large, well-powered studies, the absence of methodological equivalence between the comparators has meant that clinical questions remain genuinely contested long after the trials reported.

Modern regulatory responses — adaptive trial designs, objective performance criteria against which single-arm data can be evaluated, and the formal acceptance of real-world data as supporting evidence — represent genuine progress. But they are responses to an inherent structural constraint, not solutions to it. Device trial designers who understand this — who build their design strategy around the specific comparability limitations of their particular device category — produce better trials than those who attempt to apply pharmaceutical trial logic to a context where it does not fit.

2. Ethical and Safety Constraints: When the Device Cannot Be Undone

Drug toxicity, when identified, can usually be managed: discontinue the medication, allow washout, monitor recovery. This reversibility is a fundamental property of pharmacological intervention that shapes the entire ethical framework of drug clinical research.

For implantable and interventional devices, this reversibility does not exist — or exists only partially, at surgical cost. A coronary stent, once deployed, cannot be removed. A total joint replacement cannot be meaningfully reversed. A cochlear implant, a deep brain stimulator, a spinal cord stimulation device — these interventions reshape anatomy and physiology in ways that persist long after any trial follow-up period ends.

This irreversibility has profound ethical implications for trial design. Ethics committees evaluating implantable device trials are evaluating a qualitatively different risk than they face in most drug trials — not the risk of a transient adverse event that resolves on treatment discontinuation, but the risk of a permanent change to the patient's physiology or anatomy that may have long-term consequences that the trial cannot fully characterize.

The practical implications are several. Sample sizes are scrutinized for adequacy of safety monitoring, not just statistical power. Stopping rules must account for the possibility that an emerging safety signal cannot be reversed in patients already treated. Follow-up periods must be long enough to capture late adverse events — device fracture, polymer degradation, delayed thrombosis, late implant failure — that may not manifest within the primary endpoint window.

ISO 14155:2020, the current international standard for medical device clinical investigations, has strengthened the framework for managing these risks — requiring more rigorous risk management documentation, clearer adverse event definitions and reporting requirements, and more systematic approaches to benefit-risk assessment. The EU MDR has added mandatory post-market clinical follow-up requirements that extend the safety monitoring obligation well beyond initial approval.

These requirements are appropriate responses to the ethical reality of irreversible interventions. They are also operationally demanding — requiring clinical programs that are designed, from the outset, to sustain safety monitoring across timelines that may extend for years beyond the pivotal trial.

3. Operator Dependency: The Human Variable That Clinical Trials Cannot Randomize

Pharmaceutical trials randomize patients. Medical device trials must also, implicitly, manage the randomization of operator skill — a variable that cannot be controlled in the way that drug dose or formulation can be controlled.

The performance of most interventional medical devices is inseparable from the skill of the clinician deploying them. A coronary stent deployed by an experienced interventional cardiologist at a high-volume center will perform differently from the same stent deployed by a less experienced operator. An orthopedic implant's clinical outcomes depend on surgical technique, intraoperative decision-making, and postoperative management in ways that a drug's outcomes do not depend on the prescribing physician's technical skill.

This operator dependency creates a specific and persistent problem for medical device trials: the measured outcomes may reflect the learning curve of the operators as much as the intrinsic performance of the device. Early in a trial, as operators become familiar with a new device, outcomes may be systematically worse than they will be in mature commercial use. Conversely, a trial conducted exclusively at high-volume expert centers may generate outcomes that are not reproducible in the broader clinical community where the device will actually be used.

The clinical trial literature contains multiple examples of devices that performed well in pivotal trials conducted at expert centers and less well in post-market studies conducted across a broader operator base — a discrepancy that reflects operator dependency rather than any change in the device itself.

Managing this constraint requires explicit design choices: pre-defined operator qualification criteria, structured proctoring programs for trial centers, monitoring of center-level outcome variation as a quality control measure, and — increasingly — explicit analysis of outcomes by operator volume and experience as pre-specified secondary analyses. Acknowledging the learning curve in the statistical analysis plan, rather than treating it as a confound to be suppressed, produces more honest and more regulatory-credible results.

4. The Innovation Gap: When Technology Moves Faster Than Evidence

The product development cycle in medical devices is fundamentally different from pharmaceuticals — and it creates a constraint that has no direct parallel in drug development.

A pharmaceutical compound, once defined, remains chemically identical throughout its development program and commercial life. The drug that was studied in Phase I is, molecularly, the same drug that is eventually approved. Iterative improvements to formulation or delivery system require bridging studies, but the active pharmaceutical ingredient does not change.

Medical devices are continuously iterated. A cardiovascular stent in its fifth generation may differ from its first in strut thickness, polymer composition, drug elution kinetics, and delivery system design — changes that materially affect clinical performance but occur on a product development cycle measured in months rather than years. A surgical robot evolves through software updates, instrument design changes, and procedural refinements that happen continuously during and after the trial period.

The practical consequence is that by the time a pivotal device trial reports, the device that was studied may have been superseded by a next-generation iteration that is already in clinical use. The trial evidence base — generated for the previous generation — may not be fully applicable to the current commercial device, creating a persistent gap between the available clinical evidence and the device that clinicians are actually using.

This is not a theoretical concern. It has been a recurring feature of coronary intervention research, where the rapid succession of stent generations has meant that trial evidence often lags behind commercial practice by at least one device generation. Similar dynamics operate in structural heart disease, neuromodulation, and surgical robotics.

Regulatory frameworks are adapting — the FDA's Breakthrough Devices Program provides accelerated pathways for truly innovative devices, and both the FDA and EMA have mechanisms for using real-world performance data from earlier generations to support evidence packages for iterative improvements. But the fundamental tension between continuous innovation and the slower cadence of rigorous clinical evidence generation remains a defining feature of the device research landscape.

5. Clinical Endpoints: The Challenge of Measuring What Matters

Pharmaceutical trials can often rely on biological endpoints — plasma drug concentrations, laboratory biomarkers, imaging findings — that provide objective, reproducible measures of pharmacological effect. For device trials, the question of what to measure is frequently more complex, more contested, and more consequential.

The primary challenge is that device performance and patient outcomes are related but not identical — and choosing between them as the primary endpoint has significant implications for trial design, sample size, and interpretability.

Device performance metrics — deployment success rates, device integrity, mechanical performance — are important for regulatory evaluation but do not directly address the question patients and clinicians care about most: does this device improve how patients feel and function? Patient-reported outcomes address this question directly but are subject to placebo effect, response bias, and the particular difficulties of blinding that characterize device research.

Hard clinical endpoints — mortality, myocardial infarction, stroke, reoperation — provide unambiguous clinical meaning but require large sample sizes and long follow-up periods to accumulate adequate events, making them impractical for many device categories. Composite endpoints combine multiple outcomes to improve statistical efficiency but create interpretive challenges when the components move in different directions.

The current regulatory trend — visible in both FDA guidance and the EU MDR's clinical evaluation requirements — is toward endpoints that are simultaneously device-specific, clinically meaningful, and validated in the relevant patient population. Objective performance criteria established from historical data provide a benchmark against which single-arm data can be evaluated — a design approach that is increasingly accepted for devices where a randomized comparator is not feasible. Patient-reported outcome measures, when properly validated and consistently administered, are gaining regulatory acceptance as primary endpoints for devices where patient experience is the central outcome.

6. The Regulatory Evolution: Higher Standards, Greater Complexity

The regulatory landscape for medical devices has undergone a more significant transformation over the past decade than almost any other area of clinical research — and the trajectory is toward higher evidentiary standards, not lower ones.

The EU MDR, which came into full effect following a transition period ending in 2024 for most device categories, represents the most consequential regulatory change in the European device market in decades. Its requirements — substantially more rigorous clinical evidence for CE marking, mandatory post-market clinical follow-up as a condition of continued market access, periodic safety update reports, and the elimination of many of the equivalence pathways that previously allowed devices to reach market on the basis of historical data — have fundamentally changed what it means to have a clinical development strategy for a device seeking European approval.

In the United States, the FDA's Breakthrough Devices Program has provided expedited pathways for genuinely innovative devices, while the agency's increasing acceptance of real-world evidence as a component of pre-market submissions has opened new routes to approval for devices with limited feasibility of randomized controlled trials. The FDA's emphasis on Total Product Life Cycle (TPLC) regulation — treating clinical evidence as a continuous obligation rather than a pre-market milestone — mirrors the EU MDR's post-market surveillance requirements and signals a global convergence toward lifecycle-based evidence generation.

In India, the Medical Devices Rules 2017 and their subsequent amendments have replaced the notification-based approach that previously governed most device market entry with a formal clinical investigation approval requirement under CDSCO. This change, which aligns India's framework more closely with international standards, has introduced formal ethics committee oversight requirements, clinical investigation approval processes, and registration obligations that represent a substantial increase in regulatory rigor compared to the previous framework. For international device companies with Indian market ambitions, and for Indian device manufacturers seeking global regulatory credibility, navigating this evolving landscape requires regulatory expertise that was not necessary a decade ago.

7. Real-World Evidence: The Promise and the Complexity

The integration of real-world evidence into medical device clinical evaluation represents one of the most significant methodological shifts of the past decade — and one that is both genuinely valuable and genuinely complex.

The promise is clear. Traditional randomized controlled trials, conducted in carefully selected patient populations at high-volume expert centers with intensive monitoring and protocol-defined follow-up, generate evidence that is scientifically rigorous but often not representative of the patients, operators, and settings that will use the device in routine clinical practice. Real-world evidence — drawn from registries, electronic health records, claims databases, and post-market surveillance programs — can address these limitations, providing insight into device performance across the full range of patients and settings where it is used.

For regulatory purposes, real-world evidence is increasingly accepted as supporting evidence for pre-market submissions, as a component of post-market clinical follow-up obligations, and — in some cases — as a primary evidence source for iterative device improvements where a new randomized trial would be disproportionate to the magnitude of the design change. The FDA's real-world evidence framework and the EU MDR's post-market clinical follow-up requirements both reflect this acceptance.

The complexity lies in execution. Real-world data is inherently messier than trial data — missing values, inconsistent definitions, variable data quality across sites, confounding by indication that cannot be addressed by randomization, and selection biases that may not be apparent in the data itself. Converting real-world data into regulatory-grade real-world evidence requires methodological rigor that is comparable to, and in some respects more demanding than, the rigor applied in traditional trial design. Appropriate study designs — prospective registries with pre-defined endpoints, propensity-matched comparative analyses, Bayesian synthesis with historical trial data — can generate evidence of sufficient quality for regulatory purposes, but only when designed and executed with that purpose explicitly in mind from the outset.

Navigating Constraint as Competitive Advantage

The constraints described in this article are not going to disappear. The absence of perfect controls is structural. Operator dependency is inherent to the nature of device-based interventions. The innovation gap is a feature of the device industry's product development model. Regulatory expectations will continue to rise. Real-world evidence will continue to require methodological sophistication to generate credibly.

For device companies and their clinical research partners, the question is not whether these constraints exist — they do — but whether the clinical program is designed by people who understand them deeply enough to work within them effectively.

A study design that honestly addresses the comparability limitations of its control group. An endpoint strategy that gives regulators and clinicians what they actually need to make decisions. An operator qualification and monitoring program that manages learning curve effects rather than suppressing them. A real-world evidence strategy that is built into the clinical program from day one rather than retrofitted after the randomized trial has reported. A regulatory strategy that accounts for the specific requirements of each target jurisdiction and designs the evidence package to meet the highest applicable standard from the outset.

These are the hallmarks of sophisticated medical device clinical research — and they are increasingly the differentiating factors in a field where the regulatory bar is rising and the cost of an inadequate clinical program has never been higher.

At Genelife Clinical Research, our medical device clinical research capabilities are built around a deep understanding of the constraints that make this field distinctive — and the methodological and regulatory tools that are available to address them. We work with device companies to design and execute clinical programs that generate evidence meeting the standards of CDSCO, US FDA, and EU MDR, from early feasibility through post-market clinical follow-up.

---

To learn more about Genelife's medical device clinical research capabilities, visit genelifecr.com.

Related Insights

Our expertise in Medical Devices

CDSCO Approval Process for Clinical Trials in India: Complete Guide

Real World Evidence (RWE) in Clinical Research